Alverix and BD partner to develop point of care infectious disease diagnostic assay systems

As consumers begin to take greater ownership of their own healthcare, there is a growing demand for accessibility to diagnostic testing. Alverix, Inc. and BD (Becton, Dickinson and Company) are on the cutting edge of this trend and today announced an agreement to produce assay systems at the point-of-care (POC) that will improve infectious disease diagnoses.

“The cost and efficiency of critical diagnoses will be greatly augmented as more diagnostic tests are performed more quickly at the point of care”

When combined with existing diagnostic tests, or with assays currently being developed, Alverix's devices enable central laboratory quality results to be realized in any location where rapid test information is critical to patient care. Until now, this level of performance required expensive, bench-top instrumentation. In contrast, Alverix's detection devices provide immediate, accurate results at POC - in doctors' offices - for a fraction of the cost and turn around time of traditional methods.

"The cost and efficiency of critical diagnoses will be greatly augmented as more diagnostic tests are performed more quickly at the point of care," said Ric Tarbox, CEO of Alverix. "Our technology has the potential to revolutionize medical diagnostics and dramatically improve patient care by enabling more sensitive, affordable, immediate and accurate testing for acute and chronic health conditions, in all near- patient settings. By working with BD, we are able to help expand the accessibility of existing and new assays and promote the next generation of diagnostics that will be designed for broad use by healthcare professionals and patients."

"Alverix's technology delivers greater sensitivity and accuracy at a greatly reduced cost to traditional bench-top instruments," said Greg Miziolek, VP, BD Diagnostics, Point of Care. "In line with BD's purpose of 'Helping all people live healthy lives,' the Company strives to improve the speed and accuracy of infectious disease diagnosis. We seek to introduce faster, more accurate tests that have the potential to enable physicians to initiate appropriate treatment sooner, speed the diagnosis of infectious diseases, and improve patient outcomes."